Poster Rounds with the Professors 01   

01 – PERIPHERAL PD-1+REGULATORY T CELLS FOR PREDICTING TREATMENT RESPONSE TO PARP INHIBITOR MAINTENANCE IN PATIENTS WITH EPITHELIAL OVARIAN CANCER
🎙️Junsik Park, (Korea, Republic of)

02 – MULTICENTER REAL-WORLD EXPERIENCES OF PARPI RECHALLENGE IN PATIENTS WITH OVARIAN CANCER IN CHINA
🎙️Jin Li, (China)

03 – TREATMENT-FREE SURVIVAL ANALYSES FOR TRIALS OF PARP INHIBITORS MAINTENANCE THERAPY IN RELAPSED OVARIAN CANCER
🎙️Yulian Chen, (China)

04 – A SINGLE-ARM, PHASE II STUDY OF NIRAPARIB AND BEVACIZUMAB MAINTENANCE IN PATIENTS WITH PLATINUM-SENSITIVE, RECURRENT OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR (KGOG 3056/NIRVANA-R)
🎙️Hyun-Woong Cho, (Korea, Republic of)

 

Poster Rounds with the Professors 02   

21 – CHEMOTHERAPY COMPLETION IN THE OLDER ADULTS WITH EPITHELIAL OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER AT A UNIVERSITY HOSPITAL IN THAILAND
🎙️Natacha Phoolcharoen, (Thailand)

22 – A RETROSPECTIVE STUDY ON THE COMPARISON OF RESPONSIVENESS OF EACH CHEMOTHERAPY FOR RECURRENT OVARIAN CANCER AFTER MAINTENANCE TREATMENT WITH PARP INHIBITORS
🎙️Jung Chul Kim, (Korea, Republic of)

23 – PREVALENCE AND EFFECT OF MALNUTRITION ON SURGICAL AND ONCOLOGICAL OUTCOMES IN ADVANCED OVARIAN CANCER PATIENTS
🎙️Kittithach Pischart, (Thailand)

24 – PROGNOSTIC IMPACT OF ERYTHROPOIETIN-STIMULATING AGENTS DURING FRONT–LINE CHEMOTHERAPY IN PATIENTS WITH OVARIAN CANCER: A KOREAN MULTICENTER COHORT STUDY
🎙️Seung-Hyuk Shim, (Korea, Republic of)

 

Poster Rounds with the Professors 03   

33 – A PREDICTIVE MODEL FOR LYMPH NODE METASTASIS USING A TUMOR LOCATION IN PRESUMED EARLY-STAGE ENDOMETRIOID ENDOMETRIAL CANCER PATIENTS
🎙️Jeeyeon Kim, (Korea, Republic of)

34 – ONCOLOGIC OUTCOMES OF ROBOT-ASSISTED LAPAROSCOPY VERSUS LAPAROSCOPY FOR THE TREATMENT OF APPARENT EARLY STAGE ENDOMETRIOID ADENOCARCINOMA OF THE UTERUS
🎙️Yu Hui Lim, (United States of America)

35 – PROTEOGENOMICS DELINEATE PATHOGENESIS, MOLECULAR CHARACTERISTICS, AND PREDICTORS OF PROGESTIN RESPONSE IN EARLY-ONSET ENDOMETRIOID ENDOMETRIAL CANCER
🎙️Gang Chen, (China)

36 – PROTEOGENOMICS DECIPHER DISTINCT METASTASIS PATTERNS AND BIOMARKERS OF ENDOMETRIAL CARCINOMA
🎙️Gang Chen, (China)

 

Poster Rounds with the Professors 04   

53 – OUTCOMES ASSOCIATED WITH POSTOPERATIVE CHEMOTHERAPY FOLLOWING PELVIC EXENTERATION FOR RECURRENT OR PERSISTENT GYNECOLOGIC MALIGNANCIES
🎙️Bill Zammarrelli, (United States of America)

54 – THE GENOMIC LANDSCAPE OF DISTANT METASTATIC ENDOMETRIAL CANCER
🎙️Bill Zammarrelli, (United States of America)

55 – IMPROVING THE RATE OF SAME DAY DISCHARGE IN GYNECOLOGIC ONCOLOGY PATIENTS UNDERGOING MINIMALLY INVASIVE SURGERY – AN ENHANCED RECOVERY AFTER SURGERY QUALITY IMPROVEMENT INITIATIVE
🎙️Jennifer Mateshaytis, (Canada)

56 – AVOIDING THE NEEDLE: APIXABAN FOR EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER MAJOR GYNECOLOGIC CANCER SURGERY.
🎙️Justin M. Mcginnis, (Canada)

 

Poster Rounds with the Professors 05   

65 – CLINICOPATHOLOGICAL CHARACTERISTICS AND ONCOLOGICAL OUTCOMES OF THREE SUBTYPES OF NEUROENDOCRINE CARCINOMA OF THE CERVIX: A MULTICENTER RETROSPECTIVE STUDY OF 288 PATIENTS IN CHINA
🎙️Yu Gu, (China)

66 – A PHASE II STUDY OF OXALIPLATIN WITH ORAL S-1 FOR PATIENTS WITH RECURRENT NON-SQUAMOUS CELL CARCINOMA OF UTERINE CERVIX (TOHOKU GYNECOLOGIC CANCER UNIT 206 STUDY)
🎙️Takayuki Nagasawa, (Japan)

67 – CLINICAL AND DOSIMETRIC STUDY OF OCCULT UTERINE TANDEM IMPERFECT IMPLANTATION IN HDR-BRACHYTHERAPY FOR CERVICAL CANCER
🎙️Dongling Zou, (China)

68 – TORIPALIMAB COMBINED WITH BEVACIZUMAB AND CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR REFRACTORY, RECURRENT OR METASTATIC CERVICAL CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE II TRIA
🎙️Chen Li, (China)

 

Poster Rounds with the Professors 06   

86 – 3D-PRINTED VAGINAL INDIVIDUALIZED APPLICATOR (VIA) SIMPLIFIES PROCEDURE AND OPTIMIZES DOSIMETRY FOR GYNECOLOGIC INTERSTITIAL BRACHYTHERAPY
🎙️Thomas Niedermayr, (United States of America)

87 – HPV-ASSOCIATED AND HPV-INDEPENDENT VULVAR SQUAMOUS CELL CARCINOMA: IS THERE AN IMPACT OF RESECTION MARGINS ON LOCAL RECURRENCE?
🎙️Marilyn Boo, (New Zealand)

88 – HPV SCREENING IS EFFECTIVE AGAINST VAGINAL AND VULVAR CANCERS
🎙️Maija Vahteristo, (Finland)

Poster Rounds with the Professors 07   

05 – THE COMPARISON OF THE INFLUENCE OF BOWEL RESECTION OR BOWEL TUMOR STRIPPING ON THE PROGNOSIS IN PATIENTS WITH BOWEL METASTASES ORIGINATED FROM ADVANCED OVARIAN CANCER
🎙️Zhengmao Zhang, (China)

06 – FROM PHENOTYPE TO GENOTYPE: PEROPERATIVE PREDICTION OF HRD STATUS IN EPITHELIAL OVARIAN CANCERS (EOC) BASED ON SERUM CA-125, INTRAOPERATIVE TUMOUR CHARACTERISTICS AND SURGICAL RESECTABILITY
🎙️Aarthi Jayraj, (United Kingdom)

07 – METASTATIC PATTERN OF OVARIAN CANCER DELINEATED BY TRACING THE EVOLUTION OF MITOCHONDRIAL DNA MUTATIONS
🎙️Shujuan Liu, (China)

08 – IMPACT OF ASCITES AND PERITONEAL METASTATIC LESION VOLUMES, MEASURED BY NEWLY DEVELOPED DEEP LEARNING-BASED ALGORITHM, IN ADVANCED EPITHELIAL OVARIAN CANCER
🎙️Ui Suk Kim, (Korea, Republic of)

 

Poster Rounds with the Professors 08   

17 – CLINICAL CHARACTERISTICS AND ONCOLOGICAL OUTCOMES OF RECURRENT ADULT GRANULOSA CELL TUMOR OF OVARY: A RETROSPECTIVE STUDY OF SEVENTY PATIENTS
🎙️Yu Gu, (China)

18 – ASSESSING CANCER-RELATED FINANCIAL TOXICITY AND ASSOCIATION WITH PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RECURRENT OVARIAN CANCER
🎙️Larissa Meyer, (United States of America)

19 – SENAPARIB, A PARP INHIBITOR, IN PATIENTS WITH BRCA1/2 MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER: SUBGROUP ANALYSIS FROM SABRINA STUDY.
🎙️Xiaohua Wu, (China)

20 – A PHASE 2, SINGLE ARM, PROSPECTIVE CLINICAL STUDY OF ANTITINIB HYDROCHLORIDE COMBINED WITH LETROZOLE IN THE TREATMENT OF PLATINUM RESISTANT RECURRENT OVARIAN CANCER
🎙️Xipeng Wang, (China)

 

Poster Rounds with the Professors 09   

37 – LOW ACCURACY OF PREOPERATIVE SAMPLING FOR DIAGNOSING UTERINE CARCINOSARCOMA
🎙️Eveline Pham, (Netherlands)

38 – SURVIVAL BENEFIT OF CYTOREDUCTIVE SURGERY IN PATIENTS WITH PRIMARY STAGE IV ENDOMETRIAL CANCER: A SYSTEMATIC REVIEW & META-ANALYSIS.
🎙️Eveline Pham, (Netherlands)

39 – A NOVEL IMMUNE SUBTYPE CLASSIFICATION OF THE COPY-NUMBER HIGH ENDOMETRIAL CANCER
🎙️Mingyi Mao, (China)

40 – EVALUATION OF THE COMBINATION LENVATINIB AND PEMBROLIZUMAB IN ENDOMETRIAL CANCER; A REAL WORLD MULTI-INSTITUTIONAL REVIEW OF PRACTICE PATTERNS, EFFICACY AND TOLERABILITY
🎙️Angeles Alvarez Secord, (United States of America)

 

Poster Rounds with the Professors 10   

49 – VALUE OF THE NEW ENDOMETRIAL CANCER RISK MOLECULAR CATEGORIZATION SYSTEM 2020 ESGO/ESTRO/ESP IN PREDICTING SURVIVAL AND RECURRENCE
🎙️Yung-Taek Ouh, (Korea, Republic of)

50 – MOLECULAR PROFILING OF P53 MUTANT ENDOMETRIAL CANCER REVEALS DISTINCT SUBGROUPS WITH OPPORTUNITIES FOR PERSONALIZED THERAPEUTIC APPROACHES
🎙️Felix Blanc-Durand, (France)

51 – MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER: DOSTARLIMAB PLUS CHEMOTHERAPY COMPARED WITH CHEMOTHERAPY ALONE IN THE ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL
🎙️Zoltan Novák, (Hungary)

 

Poster Rounds with the Professors 11   

69 – TEN-YEAR OUTCOMES FOLLOWING LAPAROSCOPIC AND OPEN ABDOMINAL RADICAL HYSTERECTOMY FOR “LOW-RISK” EARLY-STAGE CERVICAL CANCER: A PROPENSITY-SCORE BASED ANALYSIS
🎙️Giorgio Bogani, (Italy)

70 – NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER. CAN CLINICAL-PATHOLOGIC FACTORS AND BIOMARKERS EXPRESSION COMBINED MODEL PREDICT THE CHEMORESPONSIVITY?
🎙️Giorgio Bogani, (Italy)

71 – OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AND RADICAL HYSTERECTOMY FOR LOCALLY ADVANCED CERVICAL CANCER AT KIGALI UNIVERSITY TEACHING HOSPITAL, RWANDA
🎙️Lisa Bazzett-Matabele, (Botswana)

72 – THE INCIDENCE OF PERIOPERATIVE LYMPHATIC COMPLICATIONS AFTER RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY BETWEEN ROBOTIC AND LAPAROSCOPIC APPROACH: A SYSTEMIC REVIEW AND META-ANALYSIS
🎙️Jong Ha Hwang, (Korea, Republic of)

 

Poster Rounds with the Professors 12   

81 – SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC) OUTCOMES IN AN AVERAGE RISK POPULATION
🎙️Janice Kwon, (Canada)

82 – GYNECOLOGIC ONCOLOGISTS’ PRACTICE PATTERNS AND ASSOCIATED BARRIERS TOWARD PALLIATIVE-HOSPICE CARE: A SURVEY OF THE KOREAN GYNECOLOGIC ONCOLOGY GROUP
🎙️Ga Won Yim, (Korea, Republic of)

83 – ARTIFICIAL INTELLIGENCE-BASED DIAGNOSTIC SYSTEM FOR THE DETECTION OF ABNORMAL COLPOSCOPIC FINDINGS
🎙️Akihiko Ueda, (Japan)

84 – EARLY STAGE OVARIAN IMMATURE TERATOMA: SURVEILLANCE OR CHEMOTHERAPY AFTER SURGERY? EXPERIENCE FROM CHINESE NATIONAL CENTER OF RARE DISEASE.
🎙️Xinyue Zhang, (China)

Poster Rounds with the Professors 13   

13 – PHASE I TRIAL OF TILVESTAMAB, A FUNCTION-BLOCKING ANTIBODY INHIBITING AXL, IN PLATINUM-RESISTANT/REFRACTORY HIGH GRADE SEROUS OVARIAN CANCER (PROC).
🎙️David Tan, (Singapore)

14 – INFLUENCE OF SPATIAL TUMOUR HETEROGENEITY ON HOMOLOGOUS RECOMBINATION DEFICIENCY SCORES FOR HIGH GRADE SEROUS OVARIAN CANCER PATIENTS
🎙️Christina Fotopoulou, (United Kingdom)

15 – FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER
🎙️Gottfried Konecny, (United States of America)

16 – COMPREHENSIVE SERUM GLYCOPEPTIDE SPECTRA ANALYSIS (CSGSA) TO IDENTIFY EARLY-STAGE OVARIAN CANCER
🎙️Masae Ikeda, (Japan)

 

Poster Rounds with the Professors 14   

25 – SPATIAL PROFILING OF OVARIAN CLEAR CELL CARCINOMA (OCCC) REVEALS IMMUNE-HOT FEATURES
🎙️Ya-Ting Tai, (Taiwan)

26 – DISTINCT VAGINAL MICROBIOME OVARIAN CANCER PATIENTS – A POSSIBLE SCREENING AND PROGNOSTIC BIOMARKER?
🎙️Ilan Bruchim, (Israel)

27 – EZH2/EZH1 INHIBITOR TULMIMETOSTAT (CPI-0209): PRELIMINARY PHASE II RESULTS AND FIRST BIOMARKER FINDINGS IN PATIENTS WITH ARID1A-MUTANT OVARIAN CLEAR CELL OR ENDOMETRIAL CARCINOMAS (OCCC/EC)
🎙️Anjali Thakur, (Germany)

28 – EFFORT: CLINICAL AND MOLECULAR FEATURES ASSOCIATED WITH CLINICAL BENEFIT FROM ADAVOSERTIB WITH OR WITHOUT OLAPARIB IN RECURRENT OVARIAN CANCER FOLLOWING PROGRESSION ON PARP INHIBITION (NCT03579316)
🎙️Shannon Westin, (United States of America)

 

Poster Rounds with the Professors 15   

45 – A COST-EFFECTIVENESS ANALYSIS OF HOSPITAL TREATMENT VOLUME AND SURVIVAL OUTCOMES IN PATIENTS WITH ENDOMETRIAL CANCER IN JAPAN
🎙️Hiroko Machida, (Japan)

46 – RESTAGING UTERINE CANCER PATIENTS WITH THE 2023 FIGO GUIDELINES: CLINICAL CHARACTERISTICS AND SURVIVAL DIFFERENCES.
🎙️Rosemary Senguttuvan, (United States of America)

47 – DIAGNOSTIC AND PROGNOSTIC ROLE OF CIRCULATING NEUTROPHIL EXTRACELLULAR TRAP MARKERS AND PREKALLIKREIN IN PATIENTS WITH ENDOMETRIAL CANCER
🎙️Seung Jun Lee, (Korea, Republic of)

48 – PRE-TREATMENT SYSTEMIC INFLAMMATORY MARKERS PREDICT SURVIVAL IN ENDOMETRIAL CANCER: A JAPANESE GYNAECOLOGIC ONCOLOGY GROUP (JGOG) 2043 EXPLORATORY DATA ANALYSIS
🎙️Shin Nishio, (Japan)

 

Poster Rounds with the Professors 16   

57 – METFORMIN AS AN ADJUNCT TO PROGESTIN THERAPY IN ENDOMETRIAL HYPERPLASIA AND EARLY-STAGE ENDOMETRIAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
🎙️Koleen Pasamba, (Philippines)

58 – RUCAPARIB PLUS SN38 IN SEROUS ENDOMETRIAL CANCER
🎙️Conway Xu, (United States of America)

59 – CLINICOPATHOLOGIC AND GENOMIC ANALYSIS OF UTERINE SEROUS CARCINOMAS ARISING FROM ENDOMETRIAL HYPERPLASIA
🎙️Tiffany Sia, (United States of America)

60 – GENOMIC EVOLUTION OF UTERINE LEIOMYOSARCOMA: A STUDY OF SERIAL RECURRENCES
🎙️Tiffany Sia, (United States of America)

 

Poster Rounds with the Professors 17  

77 – DETECTION OF HUMAN PAPILLOMAVIRUS CIRCULATING TUMOR DNA (CTDNA) AS A NOVEL APPROACH TO CERVICAL CANCER SCREENING AND MONITORING
🎙️Erica Mandato, (Canada)

78 – THE FEASIBILITY OF SENTINEL LYMPH NODE MAPPING USING INTRA-ABDOMINAL INDOCYANINE GREEN INJECTION IN OPEN SURGERY FOR PATIENTS WITH CERVICAL CANCER
🎙️So Hyun Nam, (Korea, Republic of)

79 – IMPACT OF THE LACC TRIAL ON THE ONCOLOGIC OUTCOMES OF CERVICAL CANCER UNDERGOING SURGICAL TREATMENT
🎙️Gabriella Schivardi, (Italy)

80 – CLINICAL CHARACTERISTICS AND TRANSCRIPTOMIC ANALYSIS OF IMMUNE ACTIVE MICROENVIRONMENT IN PULMONARY METASTATIC CERVICAL CANCER
🎙️Xuan Pei, (China)

 

Poster Rounds with the Professors 18   

89 – IMPROVED RISK PREDICTION IN HPV-ASSOCIATED ENDOCERVICAL ADENOCARCINOMA THROUGH ASSESSMENT OF BINARY SILVA PATTERN-BASED CLASSIFICATION: INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF THE INTERNATIONAL SOCIETY OF GYNECOLOGICAL PATHOLOGISTS
🎙️Paul A. Cohen, (Australia)

90 – PREDICTORS OF LIFETIME CERVICAL CANCER SCREENING AND ASSOCIATION WITH SOCIAL DETERMINANTS OF HEALTH: CROSS-SECTIONAL EVIDENCE FROM THE CANADIAN LONGITUDINAL STUDY ON AGING
🎙️Melissa Lavecchia, (Canada)

91 – CAN HPV SELF SAMPLING BE USED FOR CERVICAL CANCER SCREENING IN INDIA?
🎙️Gauravi Mishra, (India)

92 – PREVENTION AND MANAGEMENT OF CERVICAL CANCER: A GENDER-LENS REVIEW OF PROGRAMMATIC AND SOCIOCULTURAL DIMENSIONS IN BANGLADESH
🎙️Fariha Haseen, (Bangladesh)

Poster Rounds with the Professors 19   

09 – CATECHOLAMINES PROMOTE OVARIAN CANCER PROGRESSION THROUGH SECRETION OF CXC-CHEMOKINES
🎙️Ha Kyun Chang, (Korea, Republic of)

10 – COST-EFFECTIVENESS OF MAINTENANCE NIRAPARIB WITH AN INDIVIDUALIZED STARTING DOSAGE COMPARED TO ROUTINE SURVEILLANCE IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER IN CHINA
🎙️Yu Zhang, (China)

11 – PAN-GYNECOLOGIC CANCER ANALYSIS OF SOMATIC HOMOLOGOUS RECOMBINATION DEFICIENCY PATHOGENIC GENE VARIANTS: MORE PREVALENT THAN WE THINK?
🎙️Muhammad Danyal Ahsan, (United States of America)

12 – CELL-FREE DNA FROM ASCITES IDENTIFIES CLINICALLY RELEVANT VARIANTS AND TUMOUR EVOLUTION IN A COHORT OF PATIENTS WITH ADVANCED OVARIAN CANCER
🎙️Bonnita Werner, (Australia)

 

Poster Rounds with the Professors 20   

29 – THE EFFICACY OF METFORMIN IN MEGESTROL ACETATE-BASED FERTILITY-SPARING TREATMENT FOR PATIENTS WITH ENDOMETRIAL ATYPICAL HYPERPLASIA AND ENDOMETRIAL CANCER: LONG-TERM OUTCOMES OF A RANDOMISED CONTROLLED TRIAL
🎙️Youting Dong, (China)

30 – UTERINE TRANSPOSITION IN THE TREATMENT OF INVASIVE CERVICAL CANCER FOR PRESERVE FERTILITY
🎙️Vitaly Antipov, (Russian Federation)

31 – MICRORNA-DEPENDENT INHIBITION OF WEE1 CONTROLS CANCER STEM-LIKE CHARACTERISTICS AND MALIGNANT BEHAVIOR IN OVARIAN CANCER
🎙️Woo Yeon Hwang, (Korea, Republic of)

32 – A MULTICENTRE RANDOMISED CONTOLLED TRIAL ON THE OUTCOMES OF FERTILITY SPARING TREATMENT OF ATYPICAL ENDOMETRIAL HYPERPLASIA
🎙️Charissa Goh, (Singapore)

 

Poster Rounds with the Professors 21   

41 – PAX2 IS REGULATED BY ESTROGEN/PROGESTERONE THROUGH PROMOTER METHYLATION IN ENDOMETRIOID ADENOCARCINOMA AND TAKE THE IMPORTANT ROLE IN CARCINOGENESIS VIA THE AKT/MTOR SIGNALING PATHWAY
🎙️Qingping Jiang, (China)

42 – CLINICAL IMPACT OF ULTRASTAGING OF SENTINEL LYMPH NODE MAPPING WITH INDOCYANINE GREEN INJECTION IN PATIENTS WITH ENDOMETRIAL CANCER
🎙️Sang Hyun Cho, (Korea, Republic of)

43 – REFINING COPY NUMBER-LOW ENDOMETRIAL CARCINOMA BY ESTROGEN RECEPTOR IMMUNOHISTOCHEMISTRY
🎙️Clarissa Lam, (United States of America)

44 – ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC SURGERY FOR ENDOMETRIAL CANCER: LONG-TERM COMPARISON OF OUTCOMES
🎙️Kyung Jin Eoh, (Korea, Republic of)

 

Poster Rounds with the Professors 22   

62 – EFFICACY AND SAFETY OF BVAC-C IN HPV TYPE 16 OR 18 POSITIVE CERVICAL CARCINOMA WHO FAILED 1ST PLATINUM BASED CHEMOTHERAPY: A PHASE I/IIA STUDY
🎙️Chel Hun Choi, (Korea, Republic of)

63 – COMPARISONS OF SURVIVAL OUTCOMES OF LAPAROSCOPIC VERSUS OPEN RADICAL HYSTERECTOMY IN EARLY CERVICAL CANCER WITH INCIDENTALLY IDENTIFIED PATHOLOGIC HIGH-RISK FACTORS
🎙️Seung Jun Lee, (Korea, Republic of)

64 – A RETROSPECTIVE STUDY OF BEVACIZUMAB COMBINED WITH CHEMORADIOTHERAPY IN PRIMARY TREATMENT OF STAGE III-IVA CERVICAL CANCER
🎙️Mingzi Tan, (China)

 

Poster Rounds with the Professors 23   

73 – COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE OR 2-DOSE OF BIVALENT, QUADRIVALENT, OR NONAVALENT HPV VACCINE IN A LOW/MIDDLE INCOME COUNTRY SETTING.
🎙️Wichai Termrungruanglert, (Thailand)

74 – PREVALENCE OF HIGH-RISK HPV DNA IN A SEMI-URBAN POPULATION OF UTTARAKHAND, INDIA USING A POINT-OF-CARE TEST
🎙️Shalini Rajaram, (India)

75 – REAL-WORLD HEALTH ECONOMIC EVALUATION OF DNA METHYLATION MARKER FOR TRIAGE OF HRHPV-POSITIVE WOMEN IN CERVICAL CANCER SCREENING IN CHINA
🎙️Hsiang Yu Chuang, (China)